An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...

At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not ...

When the U.S. Food and Drug Administration (FDA) convened a public expert panel to review the use of selective serotonin ...

Members of an advisory panel have proposed adding warning labels to some medication about adverse maternal and fetal risks in ...

Members of an FDA expert panel discussed the risks and benefits of selective serotonin reuptake inhibitors, or SSRIs, for ...

Experts on the panel shared many of the same views around SSRIs, arguing the risks of the drugs during pregnancy are greater ...

A Food and Drug Administration panel discussing the use of antidepressants during pregnancy Monday largely amounted to ...

The U.S. Food and Drug Administration is turning its attention to selective serotonin reuptake inhibitors, a class of antidepressant drugs long criticized by Health and Human Services ...

FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s ...

Currently, there's only one drug on the market that's FDA-approved to treat postpartum depression. The drug, called Zulresso, is only available through 60-hour, one-time infusion, and can cost as ...